Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer

BACKGROUND: Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)–mutated NSCLC remains unknown. The SINDAS tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao-Shan, Bai, Yi-Feng, Verma, Vivek, Yu, Rui-Lian, Tian, Wei, Ao, Rui, Deng, Ying, Zhu, Xue-Qiang, Liu, Hao, Pan, Hai-Xia, Yang, Lan, Bai, Han-Song, Luo, Xing, Guo, Yan, Zhou, Ming-Xiu, Sun, Yue-Mei, Zhang, Zi-Can, Li, Si-Min, Cheng, Xue, Tan, Bang-Xian, Han, Liang-Fu, Liu, Ying-Yi, Zhang, Kai, Zeng, Fan-Xin, Jia, Lin, Hao, Xin-Bao, Wang, You-Yu, Feng, Gang, Xie, Ke, Lu, You, Zeng, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248839/
https://www.ncbi.nlm.nih.gov/pubmed/35094066
http://dx.doi.org/10.1093/jnci/djac015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248839/
https://www.ncbi.nlm.nih.gov/pubmed/35094066
http://dx.doi.org/10.1093/jnci/djac015

Ejemplares similares